NCT06794645View on ClinicalTrials.gov

Pembrolizumab and Pemetrexed for Progressive Chordoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
ChordomasChordoma
Interventions
DRUG

Pembrolizumab

pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle

DRUG

Pemetrexed Phase 2

pemetrexed 900 mg/m2 IV on Day 1 of each 21-day treatment cycle and supportive medications (folic acid, vitamin B12, and dexamethasone).

Trial Locations (1)

90404

RECRUITING

Providence Saint John's Health Center, Santa Monica

All Listed Sponsors
collaborator

Chordoma Foundation

OTHER

lead

Saint John's Cancer Institute

OTHER